Ecopha Biotech announces strategic cross-border model
Australian biotech company Ecopha Biotech Pty Ltd has announced that, to support the global commercialisation of its proprietary ecopha.bio technology, it is advancing an Australia–India strategy. The company said it is a step towards building a world-scale Pongamia-based bioeconomy platform — exploring how Australian-developed biotechnology can be paired with India’s industrial capacity to enable large-scale production.
A dual-output model that converts Pongamia oil, a non-food, low-carbon feedstock, into both sustainable aviation fuel (SAF) and marine-biodegradable PHA bioplastics is at the centre of Ecopha Biotech’s platform — SAF being engineered to support aviation’s transition to lower-emissions energy and PHA bioplastics being a next-generation material designed to biodegrade safely, including in natural environments.

The cross-border model will see Australia as the technology and innovation hub for ecopha.bio technology and India as a potential large-scale production and feedstock hub. A single facility at full operational scale is projected, the company said, to process up to 1 million tonnes of Pongamia oil annually, with the potential to generate 700,000 tonnes of SAF, 200,000 tonnes of PHA bioplastics and approximately $3.2 billion in annual revenue.

“This collaboration is not just about production, it’s about building a new bioeconomy system,” said CEO and Co-founder of Ecopha Biotech Dr Wilson Ling. “By uniting Australian innovation with Indian scale, we are creating a sovereign, scalable solution to the twin challenges of climate change and plastic pollution. This dual-output model shows that sustainability and high-margin profitability can go hand in hand.”
Cayman Chemical Autophagy-Focused Screening Library (96-Well)
The Cayman Chemical Autophagy-Focused Screening Library (96-Well) is for screening a variety of...
Dharmacon ON-TARGETplus siRNA for precision gene knockdown
Dharmacon ON-TARGETplus siRNAs by Revvity combine a patented dual-strand modification pattern...
AdipoGen Life Sciences InVivoKines recombinant fusion proteins
InVivoKines are recombinant fusion proteins for immunotherapeutic, preclinical and translational...
